USPTO serial 76320908
SYNERDRUG
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- JOHNSON, AISHA CLARKE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SYNERDRUG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Viviana Amzel, Esq.
VIVIANA AMZEL ESQ EPIGENESIS PHARMACEUTICALS, INC7 CLARKE DRCRANBURY, NJ 08512-3620UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | describing pharmaceutical preparations that act synergistically with other drugs, for administration via respiratory airways, including small molecules and nucleotide sequences for medical use (or Respiratory Anti-sense OligoNucleotides (RASON)), including aerosolized oligonucleotide preparations for the treatment of human and non-human animal respiratory, immune, endocrine, cardiovascular, neoplastic and central nervous ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, particularly testing, preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, administration of certain drugs, including adenosine and other drugs for, for example, treating Supra Ventricular Tachycardia (SVT), adenosine stress tests, infantile Respiratory Distress Syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemia, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as all metastatic cancers, e.g. cancers which metastasized to the lung(s), breast, liver and prostate included | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 22, 2003 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 28, 2002 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 5, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 13, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 12, 2001 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 11, 2001 | DOCK | ASSIGNED TO EXAMINER | — |